{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:47:22Z","timestamp":1791042442314,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/mcp.0b013e32833eebfd","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T12:13:40Z","timestamp":1283429620000},"page":"604-610","source":"Crossref","is-referenced-by-count":95,"title":["Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity"],"prefix":"10.1097","volume":"16","author":[{"given":"Andrew","family":"Prayle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210206","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"J Pediatr"},{"key":"R2-14-20210206","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis: the TOPIC study \u2013 a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"R4-14-20210206","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s15010-009-8117-4","article-title":"Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"R6-14-20210206","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-14-20210206","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"Doring","year":"2000","journal-title":"Eur Respir J"},{"key":"R9-14-20210206","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1445-5994.2008.01787.x","article-title":"Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?","volume":"39","author":"Soulsby","year":"2009","journal-title":"Intern Med J"},{"key":"R10-14-20210206","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ppul.20985","article-title":"A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis","volume":"44","author":"Van Meter","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"R11-14-20210206","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1440-1754.2006.00944.x","article-title":"Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis","volume":"42","author":"Massie","year":"2006","journal-title":"J Paediatr Child Health"},{"key":"R12-14-20210206","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","article-title":"Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis: caution with trough concentrations","volume":"6","author":"Coulthard","year":"2007","journal-title":"J Cyst Fibros"},{"key":"R14-14-20210206","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur Respir J"},{"key":"R15-14-20210206","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of inhaled antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R16-14-20210206","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcf.2009.03.001","article-title":"Implementation of European standards of care for cystic fibrosis: control and treatment of infection","volume":"8","author":"Elborn","year":"2009","journal-title":"J Cyst Fibros"},{"key":"R17-14-20210206","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R18-14-20210206","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/jac\/dkn422","article-title":"Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa","volume":"62","author":"Halwani","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R19-14-20210206","doi-asserted-by":"crossref","first-page":"e5724","DOI":"10.1371\/journal.pone.0005724","article-title":"Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis","volume":"4","author":"Alipour","year":"2009","journal-title":"PLoS One"},{"key":"R20-14-20210206","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60099-5","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin [Arikace(TM)] in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"7","author":"Dupont","year":"2008","journal-title":"J Cyst Fibros"},{"key":"R21-14-20210206","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11095-009-9825-2","article-title":"Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency","volume":"26","author":"Parlati","year":"2009","journal-title":"Pharm Res"},{"key":"R22-14-20210206","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"R23-14-20210206","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"Early antipseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study","volume":"30","author":"Treggiari","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"R24-14-20210206","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01169-07","article-title":"Clinical and economic impact of common multidrug-resistant Gram-negative bacilli","volume":"52","author":"Giske","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-14-20210206","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ppul.21198","article-title":"Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008","volume":"45","author":"Emerson","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"R26-14-20210206","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ppul.21011","article-title":"Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients","volume":"44","author":"Bjarnsholt","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"R27-14-20210206","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1128\/AAC.00507-08","article-title":"Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa","volume":"52","author":"Schurek","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-14-20210206","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ppul.20671","article-title":"Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection","volume":"42","author":"Moriarty","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"R30-14-20210206","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1128\/AAC.00269-09","article-title":"Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis","volume":"53","author":"Foweraker","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-14-20210206","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thx.2007.088757","article-title":"Case\u2013control study of acute renal failure in patients with cystic fibrosis in the UK","volume":"63","author":"Smyth","year":"2008","journal-title":"Thorax"},{"key":"R32-14-20210206","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ppul.20138","article-title":"Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use","volume":"39","author":"Al-Aloul","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"R33-14-20210206","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.ajkd.2009.04.001","article-title":"Definition and classification of CKD: the debate should be about patient prognosis \u2013 a position statement from KDOQI and KDIGO","volume":"53","author":"Eckardt","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R34-14-20210206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2008.07.004","article-title":"GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis","volume":"8","author":"Beringer","year":"2009","journal-title":"J Cyst Fibros"},{"key":"R35-14-20210206","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2006.05.004","article-title":"Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients","volume":"6","author":"Al-Aloul","year":"2007","journal-title":"J Cyst Fibros"},{"key":"R36-14-20210206","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcf.2009.12.002","article-title":"What is the best method for measuring renal function in adults and children with cystic fibrosis?","volume":"9","author":"Soulsby","year":"2010","journal-title":"J Cyst Fibros"},{"key":"R37-14-20210206","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1600-6143.2005.00930.x","article-title":"Progressive chronic kidney disease after pediatric lung transplantation","volume":"5","author":"Hmiel","year":"2005","journal-title":"Am J Transplant"},{"key":"R38-14-20210206","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2009.02627.x","article-title":"Rapid decline in 51Cr-EDTA measured renal function during the first weeks following lung transplantation","volume":"9","author":"Hornum","year":"2009","journal-title":"Am J Transplant"},{"issue":"Suppl 47","key":"R39-14-20210206","first-page":"24","article-title":"Aminoglycosides, toxicity and cystic fibrosis","volume":"100","author":"Watson","year":"2007","journal-title":"J R Soc Med"},{"key":"R40-14-20210206","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","article-title":"Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis","volume":"6","author":"Touw","year":"2007","journal-title":"J Cyst Fibros"},{"key":"R41-14-20210206","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/AAC.45.9.2502-2509.2001","article-title":"Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy","volume":"45","author":"Mulheran","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-14-20210206","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.00995-05","article-title":"Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients","volume":"50","author":"Mulheran","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-14-20210206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/00016480903015150","article-title":"No hearing loss after repeated courses of tobramycin in cystic fibrosis patients","volume":"130","author":"Scheenstra","year":"2010","journal-title":"Acta Otolaryngol"},{"key":"R44-14-20210206","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijporl.2010.01.021","article-title":"Hearing loss in cystic fibrosis","volume":"74","author":"Martins","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R45-14-20210206","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMc0806396","article-title":"Prevalence of mitochondrial 1555A\u2192G mutation in European children","volume":"360","author":"Bitner-Glindzicz","year":"2009","journal-title":"N Engl J Med"},{"key":"R46-14-20210206","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/FPC.0b013e328312b072","article-title":"Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population","volume":"18","author":"Conrad","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R47-14-20210206","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/GIM.0b013e318156dd07","article-title":"Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes","volume":"9","author":"Veenstra","year":"2007","journal-title":"Genet Med"},{"key":"R48-14-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/00016480801968534","article-title":"Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients","volume":"129","author":"Scheenstra","year":"2009","journal-title":"Acta Otolaryngol"}],"container-title":["Current Opinion in Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCP.0b013e32833eebfd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:33:56Z","timestamp":1620959636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00063198-201011000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mcp.0b013e32833eebfd","relation":{},"ISSN":["1070-5287"],"issn-type":[{"value":"1070-5287","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}